|Mr. Paolo Pucci||CEO & Director||819.01k||2.86M||1961|
|Mr. Peter S. Lawrence J.D.||Pres, COO, Gen. Counsel & Sec.||673.91k||N/A||1963|
|Dr. Brian Schwartz||Chief Medical Officer & Sr. VP||648.06k||1.04M||1962|
|Dr. Marc Schegerin M.D.||CFO, Head of Strategy & Treasurer||N/A||N/A||N/A|
|Mr. Blaine Schamber||Principal Accounting Officer||N/A||N/A||N/A|
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts. As of January 16, 2020, ArQule, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.
ArQule, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.